Kaleido biosciences, inc. (KLDO)
CashFlow / Yearly
Dec'19Dec'18
Operating activities:
Net loss

-86,300

-61,700

Reconciliation of net loss to net cash used in operating activities:
Depreciation and amortization

1,300

800

Loss on extinguishment of debt

-580

0

Equity-based compensation

10,068

6,964

Amortization of debt discount

37

0

Non-cash interest expense

0

62

Loss on disposal of fixed asset

0

-1

Change in fair value of warrant liability

-342

918

Change in fair value of derivative

90

195

Changes in:
Due to/from related party

0

102

Prepaid expenses and other assets

1,881

-40

Accounts payable

-684

1,837

Accrued expense and other liabilities

1,349

4,721

Net cash used in operating activities

-75,800

-46,300

Investing activities:
Purchase of property and equipment

3,586

3,002

Net cash and restricted cash used in investing activities

-3,586

-3,002

Financing activities:
Proceeds from issuance of debt

37,500

0

Repayments on debt

30,000

0

Payments for deferred issuance costs related to IPO

0

1,815

Payments of issuance and extinguishment costs related to debt

858

25

Proceeds from preferred stock financing, net of issuance costs

0

100,732

Proceeds from exercise of stock options

630

120

Payments related to capital lease

91

105

Issuance of common stock, net of issuance costs

67,761

0

Settlement of derivative liability

300

0

Net cash provided by financing activities

74,642

98,907

Net (decrease) increase in cash, cash equivalents, and restricted cash

-4,740

49,589

Supplemental cash flow information
Interest paid

881

943

Supplemental disclosure of non-cash investing and financing activities
Vesting of restricted shares

717

2,095

Reclassification of warrants to additional paid-in capital

871

0

Derivative liability related to debt

0

15

Deferred issuance costs in accounts payable and accrued expenses

0

394

Conversion of preferred stock to common stock upon closing of the initial public offering

153,226

0

Purchase of property and equipment in accounts payable and accrued expenses

385

604